3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Polycystic Ovary Syndrome
7
Neoplasms
6
Breast Neoplasms
6
Vomiting
2
Solid Tumors
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Diabetes Mellitus
2
Weight Gain
1
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Skin Toxicity
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Premature Birth
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pre-Eclampsia
1
Polycythemia Vera
1
Parathyroid Neoplasms
1
Pain, Postoperative
1
Ovarian Neoplasms
1
Nausea
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Interventions
Peripheral Blood Stem Cell Transplantation
18
fludarabine phosphate
17
Cyclophosphamide
17
Busulfan
12
Tacrolimus
11
Methotrexate
8
Cyclosporine
8
Antilymphocyte Serum
8
Whole-Body Irradiation
7
Mycophenolic Acid
7
Filgrastim
6
peginterferon alfa-2a
5
Etoposide
5
Prednisone
4
Decitabine
4
Cytarabine
4
ruxolitinib
3
fludarabine
3
Radiotherapy
3
Methylprednisolone
3
Carboplatin
3
Aspirin
3
tipifarnib
2
sonidegib
2
merphos
2
liposomal amphotericin B
2
givinostat hydrochloride
2
givinostat
2
aldesleukin
2
Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Thrombocythemia, Essential
×
Tablets
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled